Agazisiran, a potent complement Factor B siRNA, provides deep and prolonged inhibition of the alternative pathway
October, 2026
The American Society of Nephrology (ASN) Kidney Week 2026
Onvuzosiran Provides Deep and Sustained Reduction of Plasma Kallikrein Levels for the Treatment of HAE
June, 2026
European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting, June 2026
ADX-324 is novel siRNA drug that provides deep and long-lasting suppression of prekallikrein levels for HAE
February, 2026
The American Academy of Allergy, Asthma & Immunology Annual Meeting 2026
